BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21454535)

  • 1. Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms.
    Tran H; Gourrier N; Lemercier-Neuillet C; Dhaenens CM; Vautrin A; Fernandez-Gomez FJ; Arandel L; Carpentier C; Obriot H; Eddarkaoui S; Delattre L; Van Brussels E; Holt I; Morris GE; Sablonnière B; Buée L; Charlet-Berguerand N; Schraen-Maschke S; Furling D; Behm-Ansmant I; Branlant C; Caillet-Boudin ML; Sergeant N
    J Biol Chem; 2011 May; 286(18):16435-46. PubMed ID: 21454535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.
    Dhaenens CM; Schraen-Maschke S; Tran H; Vingtdeux V; Ghanem D; Leroy O; Delplanque J; Vanbrussel E; Delacourte A; Vermersch P; Maurage CA; Gruffat H; Sergeant A; Mahadevan MS; Ishiura S; Buée L; Cooper TA; Caillet-Boudin ML; Charlet-Berguerand N; Sablonnière B; Sergeant N
    Exp Neurol; 2008 Apr; 210(2):467-78. PubMed ID: 18177861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
    Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
    J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
    Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
    PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
    Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
    Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
    André LM; van Cruchten RTP; Willemse M; Wansink DG
    PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
    Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
    Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
    Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
    Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.
    Carpentier C; Ghanem D; Fernandez-Gomez FJ; Jumeau F; Philippe JV; Freyermuth F; Labudeck A; Eddarkaoui S; Dhaenens CM; Holt I; Behm-Ansmant I; Marmier-Gourrier N; Branlant C; Charlet-Berguerand N; Marie J; Schraen-Maschke S; Buée L; Sergeant N; Caillet-Boudin ML
    Biochim Biophys Acta; 2014 Apr; 1842(4):654-64. PubMed ID: 24440524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
    Dansithong W; Paul S; Comai L; Reddy S
    J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2).
    Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G
    Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic mechanisms of myotonic dystrophy.
    Lee JE; Cooper TA
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1281-6. PubMed ID: 19909263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscleblind-Like 1 and Muscleblind-Like 3 Depletion Synergistically Enhances Myotonia by Altering Clc-1 RNA Translation.
    Choi J; Personius KE; DiFranco M; Dansithong W; Yu C; Srivastava S; Dixon DM; Bhatt DB; Comai L; Vergara JL; Reddy S
    EBioMedicine; 2015 Sep; 2(9):1034-47. PubMed ID: 26501102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
    Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
    J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
    Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
    Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
    González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
    PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.
    Dhaenens CM; Tran H; Frandemiche ML; Carpentier C; Schraen-Maschke S; Sistiaga A; Goicoechea M; Eddarkaoui S; Van Brussels E; Obriot H; Labudeck A; Gevaert MH; Fernandez-Gomez F; Charlet-Berguerand N; Deramecourt V; Maurage CA; Buée L; Lopez de Munain A; Sablonnière B; Caillet-Boudin ML; Sergeant N
    Biochim Biophys Acta; 2011 Jul; 1812(7):732-42. PubMed ID: 21439371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron.
    Echeverria GV; Cooper TA
    Nucleic Acids Res; 2014 Feb; 42(3):1893-903. PubMed ID: 24185704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity.
    Terenzi F; Ladd AN
    RNA Biol; 2010; 7(1):43-55. PubMed ID: 20009516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscleblind isoforms are functionally distinct and regulate alpha-actinin splicing.
    Vicente M; Monferrer L; Poulos MG; Houseley J; Monckton DG; O'dell KM; Swanson MS; Artero RD
    Differentiation; 2007 Jun; 75(5):427-40. PubMed ID: 17309604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.